1. Centers for Disease Control and Prevention. Viral Hepatitis Surveillance—United States, 2022. Available at https://www.cdc.gov/hepatitis/statistics/2022surveillance/index.htm. Last accessed May 24, 2024.

2. Centers for Disease Control and Prevention. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction—eight states, 1998–2005. MMWR. 2008;57(6):144-148.

3. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294(16):2043-2051.

4. Hill HA, Yankey D, Elam-Evans LD, Singleton JA, Sterrett N. Vaccination coverage by age 24 months among children born in 2017 and 2018—National Immunization Survey-Child, United States, 2018–2020. MMWR. 2021;70(41):1435-1440.

5. Zhao Z, Smith PJ. Trends in vaccination coverage disparities among children, United States, 2001–2010. Vaccine. 2013;31(19):2324-2327.

6. Centers for Disease Control and Prevention. Measles Cases and Outbreaks. Available at https://www.cdc.gov/measles/data-research/index.html. Last accessed May 24, 2024.

7. Lu PJ, Hung MC, Srivastav A, et al. Surveillance of vaccination coverage among adult populations—United States, 2018. MMWR. 2021;70(SS3):1-26.

8. Schaffner W. Update on vaccine-preventable diseases: are adults in your community adequately protected? J Fam Pract. 2008;57 (4 suppl):S1-S11.

9. O'Leary ST. Immunization Schedule Updated for 2022. Available at https://publications.aap.org/aapnews/news/19567. Last accessed May 24, 2024.

10. Hall CB. The recommended childhood immunization schedule of the United States. Pediatrics. 1995;95(1):135-137.

11. Centers for Disease Control and Prevention. Past Immunization Schedules. Available at https://www.cdc.gov/vaccines/schedules/resource-library/index.html. Last accessed May 24, 2024.

12. Wodi AP, Murthy N, McNally VV, Daley MF, Cineas S. Advisory Committee on Immunization Practices recommended immunization schedule for children and adolescents aged 18 years or younger—United States, 2024. MMWR. 2024;73(1):6-10.

13. Centers for Disease Control and Prevention. Licensure of a Haemophilus influenzae type b (Hib) vaccine (Hiberix) and updated recommendations for use of Hib vaccine. MMWR. 2009;58(36):1008-1009.

14. Centers for Disease Control and Prevention. Updated recommendations of the Advisory Committee on Immunization Practice (ACIP) regarding routine poliovirus administration. MMWR. 2009;58(30);829-830.

15. Centers for Disease Control and Prevention. Notice to readers: recommended adult immunization schedule—United States, 2002–2003. MMWR. 2002;51(40):904-908.

16. Centers for Disease Control and Prevention. Cancers Linked with HPV Each Year. Available at https://www.cdc.gov/cancer/hpv/cases.html. Last accessed May 24, 2024.

17. Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics. 2016;137(3):e1-e9.

18. Advisory Committee on Immunization Practices. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR. 2015;64(41):1171-1176.

19. Murthy N, Wodi AP, McNally VV, Daley MF, Cineas S. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older—United States, 2024. MMWR. 2024;73(1):11-15.

20. Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2023–24 influenza season. MMWR. 2023;72(2):1-25.

21. Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR. 2008;57(RR7):1-60.

22. U.S. Food and Drug Administration. Highlights of Prescribing Information: FluMist Influenza Vaccine Live, Intranasal. Available at https://www.fda.gov/media/83072/download. Last accessed May 24, 2024.

23. Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2006;55(RR3):1-34.

24. Centers for Disease Control and Prevention. 2021 Final Pertussis Surveillance Report. Available at https://www.cdc.gov/measles/data-research/index.html. Last accessed May 24, 2024.

25. Kretsinger K, Broder KR, Cortese MM, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2006;55(RR17):1-33.

26. Centers for Disease Control and Prevention. Pneumococcal Disease Surveillance and Trends. Available at https://www.cdc.gov/pneumococcal/php/surveillance. Last accessed May 24, 2024.

27. Government of the District of Columbia. School Health Requirements. Available at https://dcps.dc.gov/page/school-health-requirements. Last accessed May 24, 2024.

28. American Cancer Society. Key Statistics for Cervical Cancer. Available at https://www.cancer.org/cancer/types/cervical-cancer/about/key-statistics.html. Last accessed May 24, 2024.

29. Centers for Disease Control and Prevention. Vaccines and Preventable Diseases: Who Should NOT Get Vaccinated with These Vaccines? Available at https://www.cdc.gov/vaccines/vpd/should-not-vacc.html. Last accessed May 24, 2024.

30. U.S. Food and Drug Administration. Vaccines, Blood and Biologics: Cervarix. Available at https://www.fda.gov/vaccines-blood-biologics/vaccines/cervarix. Last accessed May 24, 2024.

31. U.S. Food and Drug Administration. Vaccines, Blood and Biologics: Gardasil. Available at https://www.fda.gov/vaccines-blood-biologics/vaccines/gardasil. Last accessed May 24, 2024.

32. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2014;63(RR5):1-30.

33. Manhart LE, Holmes KK, Koutsky LA, et al. Human papillomavirus infection among sexually active young women in the United States: implications for developing a vaccination strategy. Sex Transm Dis. 2006;33(8):502-508.

34. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the U.S. JAMA. 2007;297(8):813-819.

35. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naïve women aged 16–26 years. J Infect Dis. 2009;199(7):926-935.

36. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301-314.

37. Merck. Highlights of Prescribing Information: Gardasil. Available at https://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf. Last accessed May 24, 2024.

38. Yih WK, Lieu TA, Kulldorff M, et al. Intussusception risk after rotavirus vaccination in U.S. infants. N Engl J Med. 2014;370(6):503-512.

39. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354(1):11-22.

40. Cortese MM, Parashar UD. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2009;58(RR2):1-25.

41. Centers for Disease Control and Prevention. Rotavirus. Available at https://www.cdc.gov/rotavirus/index.html. Last accessed May 24, 2024.

42. Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease. MMWR. 2005;54(RR7):1-21.

43. Centers for Disease Control and Prevention. Meningococcal Disease: Technical and Clinical Information. Available at https://www.cdc.gov/meningococcal/clinical-info.html. Last accessed May 24, 2024.

44. Fishbein DB, Broder KR, Markowitz L, Messonnier N. New, and some not-so-new, vaccines for adolescents and diseases they prevent. Pediatrics. 2008;121(suppl 1):S5-S14.

45. Centers for Disease Control and Prevention. Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use—Advisory Committee on Immunization Practices, 2010. MMWR. 2010;59(09);273.

46. U.S. Food and Drug Administration. First Vaccine Approved by FDA to Prevent Serogroup B Meningococcal Disease. Available at https://www.fda.gov/news-events/press-announcements/first-vaccine-approved-fda-prevent-serogroup-b-meningococcal-disease. Last accessed May 24, 2024.

47. Centers for Disease Control and Prevention. Notice to readers: revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11–18 years with meningococcal conjugate vaccine. MMWR. 2007;56(31):794-795.

48. Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2006;55(RR7):1-23.

49. Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR. 2018;67(3):103-108.

50. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland M, Sy LS. A population-based study of the incidence and complications of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341-1349.

51. Harbecke R, Cohen JI, Oxman MN. Herpes zoster vaccines. J Infect Dis. 2021;224(12 Suppl 2):S429-S442.

52. Centers for Disease Control and Prevention. Manual for the Surveillance of Vaccine-Preventable Diseases. 5th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2012.

53. Centers for Disease Control and Prevention. Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine—United States, 1997–2006. MMWR. 2009;58(1):1-4.

54. Centers for Disease Control and Prevention. Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. MMWR. 2012;61(21):394-395.

55. Centers for Disease Control and Prevention. Chart of Contraindications and Precautions to Commonly Used Vaccines. Available at https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html. Last accessed May 24, 2024.

56. Curran D, Oostvogels L, Heineman T, et al. Quality of life impact of a recombinant zoster vaccine in adults ≥50 years of age.J Gerontol A Biol Sci Med Sci. 2019;74(8):1231-1238.

57. Merck. Varivax (Varicella Virus Vaccine Live). Available at https://www.merck.com/product/usa/pi_circulars/v/varivax/varivax_pi.pdf. Last accessed May 24, 2024.

58. Anderson TC, Masters NB, Guo A, et al. Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years: recommendations of the Advisory Committee on Immunization Practices—United States, 2022. MMWR. 2022;71(7):80-84.

59. Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2007;56(RR4):1-40.

60. Merck. MMR-II (Measles, Mumps, and Rubella Virus Vaccine Live). Available at https://www.merck.com/product/usa/pi_circulars/m/mmr_ii/mmr_ii_pi.pdf. Last accessed May 24, 2024.

61. Merck. Highlights of Prescribing Information: RotaTeq (Rotavirus Vaccine, Live, Oral, Pentavalent). Available at https://www.merck.com/product/usa/pi_circulars/r/rotateq/rotateq_pi.pdf. Last accessed May 24, 2024.

62. GlaxoSmithKline. Highlights of Prescribing Information: Rotarix (Rotavirus Vaccine, Live, Oral). Available at https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Rotarix/pdf/ROTARIX-PI-PIL.PDF. Last accessed May 24, 2024.

63. Hales CM, Harpaz R, Ortega-Sanchez I, Bialek SR. Update on recommendations for use of herpes zoster vaccine. MMWR. 2014;63(33):729-731.

64. LexiComp Online. Available at http://online.lexi.com. Last accessed May 24, 2024.

65. GlaxoSmithKline. Highlights of Prescribing Information: Hiberix (Haemophilus b Conjugate Vaccine [Tetanus Toxoid Conjugate]). Available at https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Hiberix/pdf/HIBERIX.PDF. Last accessed May 24, 2024.

66. Centers for Disease Control and Prevention. Rotavirus Vaccine Safety. Available at https://www.cdc.gov/vaccinesafety/vaccines/rotavirus-vaccine.html. Last accessed May 24, 2024.

67. Sanofi Pasteur. Daptacel. Available at https://www.fda.gov/vaccines-blood-biologics/vaccines/daptacel. Last accessed May 24, 2024.

68. Geier DA, Geier MR. An evaluation of serious neurological disorders following immunization: a comparison of whole-cell pertussis and acellular pertussis vaccines. Brain Dev. 2004;26(5):296-300.

69. Sanofi Pasteur. Highlights of Prescribing Information: Daptacel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed). Available at https://www.fda.gov/media/74035/download. Last accessed May 24, 2024.

70. U.S. Food and Drug Administration. Infanrix. Available at https://www.fda.gov/vaccines-blood-biologics/vaccines/infanrix. Last accessed May 24, 2024.

71. GlaxoSmithKline. Highlights of Prescribing Information: Boostrix (Tetanus Toxoid, Reduced Diptheria Toxoid, and Acellular Pertussis Vaccine, Adsorbed). Available at https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Boostrix/pdf/BOOSTRIX.PDF. Last accessed May 24, 2024.

72. Sanofi Pasteur. Highlights of Prescribing Information: Adacel (Tetanus Toxoid, Reduced Diptheria Toxoid, and Acellular Pertuss is Vaccine Adsorbed). Available at https://www.fda.gov/media/119862/download. Last accessed May 24, 2024.

73. U.S. Food and Drug Administration. Highlights of Prescribing Information: Menactra Meningococcal [groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine. Available at https://www.fda.gov/media/75619/download. Last accessed May 24, 2024.

74. Wyeth Pharmaceuticals, Inc. Highlights of Prescribing Information: Prevnar 13 (Pneumococcal 13-Valent Conjugate Vaccine [Diphtheria CRM197 Protein]). Available at https://labeling.pfizer.com/showlabeling.aspx?id=501. Last accessed May 24, 2024.

75. Sanofi Pasteur. Haemophilus B Conjugate Vaccine (Tetanus Toxoid Conjugate) ActHIB. Available at https://www.fda.gov/media/74395/download. Last accessed May 24, 2024.

76. Merck. Highlights of Prescribing Information: Pneumovax 23 (Pneumococcal Vaccine Polyvalent). Available at https://www.merck.com/product/usa/pi_circulars/p/pneumovax_23/pneumovax_pi.pdf. Last accessed May 24, 2024.

77. Centers for Disease Control and Prevention. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR. 2010;59(34):1102-1106.

78. Jain A, Marshall J, Buikema A, Bancroft T, Kelly JP, Newschaffer CJ. Autism occurrence by MMR vaccine status among U.S. children with older siblings with and without autism. JAMA. 2015;313(15):1534-1540.

79. Stokley S, Jeyarajah J, Yankey D, et al. Human papillomavirus vaccination coverage among adolescents, 2007–2013, and postlicensure vaccine safety monitoring, 2006–2014—United States. MMWR. 2015;63(29);620-624.

80. U.S. Department of Health and Human Services. Vaccine Adverse Event Reporting System (VAERS). Available at https://vaers.hhs.gov. Last accessed May 24, 2024.

81. Centers for Disease Control and Prevention. Vaccine Safety Datalink (VSD) Project. Available at https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/index.html. Last accessed May 24, 2024.

82. Centers for Disease Control and Prevention. Clinical Immunization Safety Assessment (CISA) Project. Available at https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/index.html. Last accessed May 24, 2024.

83. Immunization Safety Review Committee. Immunization Safety Review: Vaccines and Autism. Washington, DC: National Academies Press; 2004.

84. Gerber JS, Offit PA. Vaccines and autism: a tale of shifting hypotheses. Clin Infect Dis. 2009;48(4):456-461.

85. Fombonne E, Zakarian R, Bennett A, Meng L, McLean-Heywood D. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics. 2006;118(1):e139-e150.

86. Hornig M, Briese T, Buie T, et al. Lack of association between measles virus vaccine and autism with enteropathy: a case-control study. PLoS One. 2008;3(9):e3140.

87. D'Souza Y, Fombonne E, Ward BJ. No evidence of persisting measles virus in peripheral blood mononuclear cells from children with autism spectrum disorder. Pediatrics. 2006;118(4):1664-1675.

88. Schechter R, Grether JK. Continuing increases in autism reported to California's developmental services system: mercury in retrograde. Arch Gen Psychiatry. 2008;65(1):19-24.

89. U.S. Food and Drug Administration. Thimerosal in Vaccines: Questions and Answers. Available at https://www.fda.gov/vaccines-blood-biologics/vaccines/thimerosal-vaccines-questions-and-answers. Last accessed May 24, 2024.

90. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354(1):23-33.

91. Hua W, Izurieta HS, Slade B, et al. Kawasaki disease after vaccination: reports to the Vaccine Adverse Event Reporting System, 1990–2007. Pediatr Infect Dis J. 2009;2(11):943-947.

92. Centers for Disease Control and Prevention. Questions & Answers About Intussusception and Rotavirus Vaccine. Available at https://www.cdc.gov/vaccines/vpd/rotavirus/about-intussusception.html. Last accessed May 24, 2024.

93. Centers for Disease Control and Prevention. Guillain-Barré Syndrome and Flu Vaccine. Available at https://www.cdc.gov/flu/prevent/guillainbarre.htm. Last accessed May 24, 2024.

94. Centers for Disease Control and Prevention. Guillain-Barré Syndrome and Menactra Meningococcal Vaccine. Available at https://www.cdc.gov/vaccinesafety/concerns/history/gbs-menactra-faqs.html. Last accessed May 24, 2024.

95. Centers for Disease Control and Prevention. Sexually Transmitted Infections Prevalence, Incidence, and Cost Estimates in the United States. Available at https://www.cdc.gov/std/statistics/prevalence-2020-at-a-glance.htm. Last accessed May 24, 2024.

96. Joyner C. Parents Homeschool to Avoid Vaccinating Their Kids. Available at http://usatoday30.usatoday.com/news/health/2008-10-21-home-school-vaccinate_N.htm. Last accessed May 24, 2024.

97. Gust DA, Darling N, Kennedy A, Schwartz B. Parents with doubts about vaccines: which vaccines and reasons why. Pediatrics. 2008;122(4):718-725.

98. Meyerhoff AS, Jacobs RJ. Do too many shots due lead to missed vaccination opportunities? Does it matter? Prev Med. 2005;41(2):540-544.

99. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. 14th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2021.

100. Kroger AT, Duchin J, Vázquez M. General Best Practice Guidelines for Immunization. Available at https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html. Last accessed May 24, 2024.

101. Centers for Disease Control and Prevention. VFC Detailed Questions and Answers for Parents. Available at https://www.cdc.gov/vaccines/programs/vfc/parents/qa-detailed.html. Last accessed May 24, 2024.

102. National Vaccine Advisory Committee. Standards for child and adolescent immunization practices. Pediatrics. 2003;112(4):958-963.

103. Adetunji Y, Macklin D, Patel R, Kinsinger L. American College of Preventive Medicine practice policy statement: childhood immunizations. Am J Prev Med. 2003;25(2)169-175.

104. Lieu TA, Capra AM, Makol J, Black SB, Shinefield HR. Effectiveness and cost-effectiveness of letters, automated telephone messages or both for underimmunized children in a health maintenance organization. Pediatrics. 1998;101(4):E3.

105. Irigoyen MM, Findley S, Earle B, Stambaugh K, Vaughan R. Impact of appointment reminders on vaccination coverage at an urban clinic. Pediatrics. 2000;106(4):919-923.

106. Dini EF, Linkins RW, Sigafoos J. The impact of computer-generated messages on childhood immunization coverage. Am J Prev Med. 2000;18(2):132-139.

107. Centers for Disease Control and Prevention. Questions About HPV Vaccine Safety. Available at https://www.cdc.gov/vaccinesafety/vaccines/hpv/hpv-safety-faqs.html. Last accessed May 24, 2024.

108. Petrosky E, Bocchini JA Jr, Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. MMWR. 2015;64(11):300-304.

109. Lu PJ, Euler GL, Jumaan AO, Harpaz R. Herpes zoster vaccination among adults aged 60 years or older in the United States: uptake of the first new vaccine to target seniors. Vaccine. 2009;27(6):882-887.

110. Poland GA, Shefer AM, McCauley M, et al. Standards for adult immunization practices. Am J Prev Med. 2003;25(2):144-150.

111. Lu PJ, Euler GL, Harpaz R. Herpes zoster vaccination among adults aged 60 years and older, in the U.S., 2008. Am J Prev Med. 2011;40(2):e1-e6.

112. Willis BC, Ndiaye SM, Hopkins DP, Shefer A. Improving influenza, pneumococcal polysaccharide, and hepatitis B vaccination coverage among adults aged <65 years at high risk: a report on recommendations of the Task Force on Community Preventive Services. MMWR. 2005;54(RR5):1-11.

113. U.S. Food and Drug Administration. FDA Approves Expanded Use of Gardasil 9 to Include Individuals 27 through 45 Years Old. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-gardasil-9-include-individuals-27-through-45-years-old. Last accessed May 24, 2024.

114. Office of Disease Prevention and Health Promotion. Increase the proportion of adolescents who get recommended doses of the HPV vaccine—IID-08. Available at https://health.gov/healthypeople/objectives-and-data/browse-objectives/vaccination/increase-proportion-adolescents-who-get-recommended-doses-hpv-vaccine-iid-08. Last accessed May 24, 2024.

115. Hviid A, Hansen JV, Frisch M, Melbye M. Measles, mumps, rubella vaccination and autism: a nationwide cohort study. Ann Intern Med. 2019;170(8):513-520.

116. Schwartz KL, Kwong JC, Deeks SL, et al. Effectiveness of pertussis vaccination and duration of immunity. CMAJ. 2016;188(16):E399-E406.

117. Centers for Disease Control and Prevention. Clinical Considerations for Use of Recombinant Zoster Vaccine (RZV, Shingrix) in Immunocompromised Adults aged ≥19 Years. Available at https://www.cdc.gov/shingles/vaccination/immunocompromised-adults.html. Last accessed May 24, 2024.

118. Centers for Disease Control and Prevention. Seasonal Influenza Vaccine Supply for the U.S. 2023-2024 Influenza Season. Available at https://www.cdc.gov/flu/prevent/vaxsupply.htm. Last accessed May 24, 2024.

119. Yih WK, Weintraub E, Kulldorff M. No risk of Guillain-Barré syndrome found after meningococcal conjugate vaccination in two large cohort studies. Pharmacoepidemiol Drug Saf. 2012;21(12):1359-1360.

120. Collins JP, Crowe SJ, Ortega-Sanchez IR, et al. Use of the Pfizer pentavalent meningococcal vaccine among persons aged ≥10 years: recommendations of the Advisory Committee on Immunization Practices―United States, 2023. MMWR. 2024;73(15):345-350.

121. Fleming-Dutra KE, Jones JM, Roper LE, et al. Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices—United States, 2023. MMWR. 2023;72(41):1115-1122.

122. Melgar M, Britton A, Roper LE, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the Advisory Committee on Immunization Practices—United States, 2023. MMWR. 2023;72(29):793-801.

123. Centers for Disease Control and Prevention. CDC Updates RSV Vaccination Recommendation for Adults. Available at https://www.cdc.gov/media/releases/2024/s-0626-vaccination-adults.html. Last accessed June 26, 2024.

1. Advisory Committee on Immunization Practices. Advisory Committee on Immunization Practices recommended immunization schedule for children and adolescents aged 18 years or younger—United States, 2022. MMWR. 2022;71(7):234-237. Available at https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf. Last accessed May 24, 2024.

2. Advisory Committee on Immunization Practices. Recommended immunization schedule for adults aged 19 years and older—United States, 2022. MMWR. 2022;71(7):229-233. Available at https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf. Last accessed May 24, 2024.